 Heres a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks Biotech Stocks Hitting 52-week highs on Jan. 28 10X Genomics Inc NASDAQ: TXG Acceleron Pharma Inc NASDAQ: XLRN announced positive Phase 2 results for its pulmonary hypertension drug Agile Therapeutics Inc NASDAQ: AGRX AtriCure Inc. NASDAQ: ATRC Avenue Therapeutics Inc NASDAQ: ATXI Catalent Inc NYSE: CTLT Hologic, Inc. NASDAQ: HOLX Insulet Corporation NASDAQ: PODD Johnson Johnson NYSE: JNJ NeoGenomics, Inc. NASDAQ: NEO Nevro Corp NYSE: NVRO Profound Medical Corp NASDAQ: PROF Quest Diagnostics Inc NYSE: DGX Rapt Therapeutics Inc NASDAQ: RAPT Satsuma Pharmaceuticals Inc NASDAQ: STSA SI-Bone Inc NASDAQ: SIBN TFF Pharmaceuticals Inc NASDAQ: TFFP Y-mAbs Therapeutics, Inc NASDAQ: YMAB H.C. Wainwright reiterated a Buy rating on shares Down In The Dumps Biotech Stocks Hitting 52-week lows on Jan. 28 Correvio Pharma Corp NASDAQ: CORV Endologix, Inc. NASDAQ: ELGX Galectin Therapeutics Inc. NASDAQ: GALT Heat Biologics Inc NASDAQ: HTBX Neuronetics Inc NASDAQ: STIM REDHILL BIOPHARS ADR NASDAQ: RDHL Salarius Pharmaceuticals Inc NASDAQ: SLRX X4 Pharmaceuticals Inc NASDAQ: XFOR VIVUS, Inc. NASDAQ: VVUS Stocks In Focus Novartis Q4 Sales, Core Income Rise, Guides to Sales, Earnings Growth Novartis AG NYSE: NVS said its fourth-quarter sales rose 8 to 12.403 million, up 8 year-over-year. 